Myriad Genetics, Inc. $MYGN Shares Sold by Northern Trust Corp

Northern Trust Corp trimmed its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,013,556 shares of the company’s stock after selling 18,576 shares during the period. Northern Trust Corp owned 1.10% of Myriad Genetics worth $8,990,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Myriad Genetics by 520.8% in the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock valued at $40,000 after acquiring an additional 3,750 shares during the last quarter. CWM LLC grew its stake in Myriad Genetics by 600.2% in the 1st quarter. CWM LLC now owns 9,796 shares of the company’s stock valued at $87,000 after acquiring an additional 8,397 shares during the last quarter. M.E. Allison & CO. Inc. acquired a new stake in Myriad Genetics in the 1st quarter valued at about $93,000. Blue Trust Inc. grew its stake in Myriad Genetics by 57.0% in the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company’s stock valued at $127,000 after acquiring an additional 5,214 shares during the last quarter. Finally, Captrust Financial Advisors grew its stake in Myriad Genetics by 36.6% in the 4th quarter. Captrust Financial Advisors now owns 20,593 shares of the company’s stock valued at $282,000 after acquiring an additional 5,519 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MYGN. Piper Sandler lowered their price objective on shares of Myriad Genetics from $12.50 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, May 15th. Scotiabank cut shares of Myriad Genetics from a “sector outperform” rating to a “sector perform” rating and lowered their price objective for the company from $20.00 to $6.00 in a research note on Wednesday, May 21st. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.45.

Myriad Genetics Trading Down 2.7%

NASDAQ:MYGN opened at $6.61 on Friday. The firm has a market cap of $615.03 million, a price-to-earnings ratio of -1.54 and a beta of 1.93. The company’s 50-day moving average is $5.41 and its two-hundred day moving average is $6.72. Myriad Genetics, Inc. has a 12-month low of $3.76 and a 12-month high of $29.30.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.